Skip to main content
Erschienen in: Journal of Cancer Survivorship 1/2014

01.03.2014

Employment following chemoradiotherapy in glioblastoma: a prospective case series

verfasst von: Cecelia Gzell, H. Wheeler, L. Guo, M. Kastelan, M. Back

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Radiotherapy (RT) and temozolomide (TMZ) for glioblastoma (GBM) has resulted in longer survival. Uncertainties exist regarding quality of survival. This study aims to determine the rate of patients returning to previous employment (EM) following treatment.

Methods

Eligible patients were diagnosed with GBM, aged 18–70 years, and treated with intensity-modulated radiotherapy to 60 Gray and TMZ (EORTC Protocol) between July 2007 and July 2011. EM was defined as paid work. Exclusion criteria included patients without histological confirmation of WHO grade IV glioblastoma, those not in paid employment in the 2-month period prior to diagnosis, or mothers of pre-school aged children not working. Data were collected on EM prior (EM pre) and after RT at 6 and 12 months (EM 6 m, EM 12 m). Rate of EM was analysed in regards to baseline performance status (ECOG), neurological deficits (MRC scale) and median survival.

Results

One hundred twelve patients were identified with median follow-up of 15.5 months and median survival 18 months (95%CI, 15–21 months). Seventy-one patients were working prior to diagnosis and eligible for analysis. Twenty patients returned to work (28 %) by EM 6 months and 19 patients (27 %) by EM 12 months. EM 6 months was strongly associated with ECOG and MRC status, with only 1 of 37 patients (3 %) with neurological deficit returning to work compared with 21 of 36 (58 %) intact patients. Of good performance status patients not returning to work, factors included presence of income insurance, family financial support or treatment-related symptoms.

Conclusion

A modest proportion of patients with GBM return back to work at 6 and 12 months following radiotherapy with the majority demonstrating the lowest level of neurological deficit prior to RT.

Implications for Cancer Survivors

Return to work following treatment does occur but it is not a common outcome.
Fußnoten
1
Source: “Statistics on Incidence, Survival Rates and Mortality Associated with Brain Tumours in Australia”, Information Paper for the Australian Brain Tumour Advocacy Group, Denise Chang, June 2003.
 
Literatur
1.
Zurück zum Zitat Chandana SR, Movva S, Arora M, Singh T. Primary brain tumors in adults. Am Fam Physician. 2008;77(10):1423–30.PubMed Chandana SR, Movva S, Arora M, Singh T. Primary brain tumors in adults. Am Fam Physician. 2008;77(10):1423–30.PubMed
2.
Zurück zum Zitat Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000–2008): findings of a multicenter Australian study. Surg Neurol Int. 2011;2:176.PubMedCentralCrossRefPubMed Dobes M, Khurana VG, Shadbolt B, Jain S, Smith SF, Smee R, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000–2008): findings of a multicenter Australian study. Surg Neurol Int. 2011;2:176.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRefPubMed Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRefPubMed
4.
Zurück zum Zitat Rønning PA, Helseth E, Meling TR, Johannesen TB. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro-oncology. 2012;14(9):1178–84.PubMedCentralCrossRefPubMed Rønning PA, Helseth E, Meling TR, Johannesen TB. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro-oncology. 2012;14(9):1178–84.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012;107(2):359–64.CrossRefPubMed Johnson DR, O’Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012;107(2):359–64.CrossRefPubMed
6.
Zurück zum Zitat Steinbach J, Blaicher H, Herrlinger U, Wick W, Nagele T, Meyermann R, et al. Surviving glioblastoma for more than 5 years: the patient’s perspective. Neurology. 2006;66(2):239–42.CrossRefPubMed Steinbach J, Blaicher H, Herrlinger U, Wick W, Nagele T, Meyermann R, et al. Surviving glioblastoma for more than 5 years: the patient’s perspective. Neurology. 2006;66(2):239–42.CrossRefPubMed
7.
Zurück zum Zitat Remer S, Murphy M. The challenges of long-term treatment outcomes in adults with malignant gliomas. Journal of Oncology Nursing. 2004;8(4):368–76 [Review] [36 refs][Erratum appears in Clin J Oncol Nurs. 2004 Oct;8(5):448].CrossRef Remer S, Murphy M. The challenges of long-term treatment outcomes in adults with malignant gliomas. Journal of Oncology Nursing. 2004;8(4):368–76 [Review] [36 refs][Erratum appears in Clin J Oncol Nurs. 2004 Oct;8(5):448].CrossRef
8.
Zurück zum Zitat Hahn C, Dunn R, Logue P, King J, Edwards C, Halperin E. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Journal of Radiation Oncology. 2003;55(4):992–9.CrossRef Hahn C, Dunn R, Logue P, King J, Edwards C, Halperin E. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Journal of Radiation Oncology. 2003;55(4):992–9.CrossRef
9.
Zurück zum Zitat Efficace F, Bottomley A. Assessing HRQOL: a neglected issue for high-grade glioma. The Lancet Oncology. 2003;4(1):11–2.CrossRefPubMed Efficace F, Bottomley A. Assessing HRQOL: a neglected issue for high-grade glioma. The Lancet Oncology. 2003;4(1):11–2.CrossRefPubMed
10.
Zurück zum Zitat Mauer M, Stupp R, Taphoorn MJB, Coens C, Osoba D, Marosi C, et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer. 2007;97(3):302–7.PubMedCentralCrossRefPubMed Mauer M, Stupp R, Taphoorn MJB, Coens C, Osoba D, Marosi C, et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer. 2007;97(3):302–7.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Meyers C, Hess K. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-Oncology. 2003;5(2):89–95.PubMedCentralPubMed Meyers C, Hess K. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-Oncology. 2003;5(2):89–95.PubMedCentralPubMed
12.
Zurück zum Zitat Kleinberg L, Wallner K, Malkin MG. Good performance status of long-term disease-free survivors of intracranial gliomas. Int J Radiat Oncol Biol Phys. 1993;26(1):129–33.CrossRefPubMed Kleinberg L, Wallner K, Malkin MG. Good performance status of long-term disease-free survivors of intracranial gliomas. Int J Radiat Oncol Biol Phys. 1993;26(1):129–33.CrossRefPubMed
13.
Zurück zum Zitat Main DS, Nowels CT, Cavender TA, Etschmaier M, Steiner JF. A qualitative study of work and work return in cancer survivors. Psycho-Oncology. 2005;14(11):992–1004.CrossRefPubMed Main DS, Nowels CT, Cavender TA, Etschmaier M, Steiner JF. A qualitative study of work and work return in cancer survivors. Psycho-Oncology. 2005;14(11):992–1004.CrossRefPubMed
14.
Zurück zum Zitat Lyons M, Orozovic N, Davis J, Newman J. Doing-being-becoming: occupational experiences of persons with life-threatening illnesses. Journal of Occupational Therapy May. 2002;56(3):285–95.CrossRef Lyons M, Orozovic N, Davis J, Newman J. Doing-being-becoming: occupational experiences of persons with life-threatening illnesses. Journal of Occupational Therapy May. 2002;56(3):285–95.CrossRef
15.
Zurück zum Zitat Freedman RI, Fesko SL. The meaning of work in the lives of people with significant disabilities: consumer and family perspectives. Journal of Rehabilitation. 1996;62(3):49–55. Freedman RI, Fesko SL. The meaning of work in the lives of people with significant disabilities: consumer and family perspectives. Journal of Rehabilitation. 1996;62(3):49–55.
16.
Zurück zum Zitat Feuerstein M, Todd BL, Moskowitz MC, Bruns GL, Stoler MR, Nassif T, et al. Work in cancer survivors: a model for practice and research. Journal of Cancer Survivorship. 2010;4(4):415–37.CrossRefPubMed Feuerstein M, Todd BL, Moskowitz MC, Bruns GL, Stoler MR, Nassif T, et al. Work in cancer survivors: a model for practice and research. Journal of Cancer Survivorship. 2010;4(4):415–37.CrossRefPubMed
17.
Zurück zum Zitat de Boer AM, Taskila T, Ojajärvi A, van Dijk FH, Verbeek JM. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA. 2009;301(7):753–62.CrossRefPubMed de Boer AM, Taskila T, Ojajärvi A, van Dijk FH, Verbeek JM. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA. 2009;301(7):753–62.CrossRefPubMed
18.
Zurück zum Zitat Dyck PJ, Boes CJ, Mulder D, Millikan C, Windebank AJ, Dyck PJB, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst. 2005;10(2):158–73.CrossRefPubMed Dyck PJ, Boes CJ, Mulder D, Millikan C, Windebank AJ, Dyck PJB, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst. 2005;10(2):158–73.CrossRefPubMed
20.
Zurück zum Zitat Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. The Lancet Oncology. 2005;6(12):937–44.CrossRefPubMed Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. The Lancet Oncology. 2005;6(12):937–44.CrossRefPubMed
21.
Zurück zum Zitat Giovagnoli A. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour. J Neurol Neurosurg Psychiatry. 1999;67(3):358–63.PubMedCentralCrossRefPubMed Giovagnoli A. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour. J Neurol Neurosurg Psychiatry. 1999;67(3):358–63.PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984;2(5):472–83.PubMed Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984;2(5):472–83.PubMed
23.
Zurück zum Zitat Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index–Cancer. Cancer. 1988;61(4):849–56.CrossRefPubMed Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index–Cancer. Cancer. 1988;61(4):849–56.CrossRefPubMed
24.
Zurück zum Zitat Butler Jr JM, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1496–501.CrossRefPubMed Butler Jr JM, Case LD, Atkins J, Frizzell B, Sanders G, Griffin P, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1496–501.CrossRefPubMed
25.
Zurück zum Zitat Spelten ER, Sprangers MAG, Verbeek JHA. Factors reported to influence the return to work of cancer survivors: a literature review. Psycho-Oncology. 2002;11(2):124–31.CrossRefPubMed Spelten ER, Sprangers MAG, Verbeek JHA. Factors reported to influence the return to work of cancer survivors: a literature review. Psycho-Oncology. 2002;11(2):124–31.CrossRefPubMed
26.
Zurück zum Zitat Kaleita TA, Wellisch DK, Cloughesy TF, Ford JM, Freeman D, Belin TR, et al. Prediction of neurocognitive outcome in adult brain tumor patients. J Neurooncol. 2004;67(1–2):245–53.CrossRefPubMed Kaleita TA, Wellisch DK, Cloughesy TF, Ford JM, Freeman D, Belin TR, et al. Prediction of neurocognitive outcome in adult brain tumor patients. J Neurooncol. 2004;67(1–2):245–53.CrossRefPubMed
27.
Zurück zum Zitat Calvio L, Feuerstein M, Hansen J, Luff GM. Cognitive limitations in occupationally active malignant brain tumour survivors. Occup Med (Lond). 2009;59(6):406–12.CrossRef Calvio L, Feuerstein M, Hansen J, Luff GM. Cognitive limitations in occupationally active malignant brain tumour survivors. Occup Med (Lond). 2009;59(6):406–12.CrossRef
Metadaten
Titel
Employment following chemoradiotherapy in glioblastoma: a prospective case series
verfasst von
Cecelia Gzell
H. Wheeler
L. Guo
M. Kastelan
M. Back
Publikationsdatum
01.03.2014
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2014
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-013-0311-9

Weitere Artikel der Ausgabe 1/2014

Journal of Cancer Survivorship 1/2014 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.